PHARMA WILSON
ActivePHARMA WILSON has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €14k and a net result of €14k. Its solvency ranks better than 14% of 10230 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.2% (low).
Checked score
Score 2025
Axes
Profitability100
Solvency1
Growth-
Stability67
Bankruptcy probability, 12 months
1.2%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €500 at 30 days only on tighter terms
Liquidity short (current ratio 0.4), and 98.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
1.3%
Return on assets
1.3%
Age of the figures
8 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 14% of 10230 sector peers (2025).
NBB · sector comparisonPosition among 10230 sector peers
Solvency
better than 14%
← weakest
strongest →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 1 filingDeviation from the deadline
2025
27 d late
← before the deadline
after the deadline →
Financials · fiscal year 2025, abbreviated schema
Equity
€14k
Total assets
€1.06M
Net result
€14k
Working capital
€-631k
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Balance-sheet composition
Assets €1.06M
Fixed assets
€645k
Current assets
€416k
Equity and liabilities €1.06M
Equity
€14k
Debt
€1.05M
Debt finances 98.7% of the balance-sheet total.
Key figures and ratios
EBITDA
€87k
Cash flow
€79k
Solvency
1.3%
Current ratio
0.40
Quick ratio
0.24
Debt / equity
73.56
ROE
100.0%
ROA
1.3%
Interest coverage
33.78
Debt
€1.05M
Debt ≤ 1 year
€1.05M
Income taxes
€5k
Staff costs
€326k
Filed annual accounts
As filed with the NBB · 2025
Balance sheet
Code2025
Assets
Total assets20/58€1.06M
Fixed assets21/28€645k
Intangible fixed assets21€638k
Tangible fixed assets22/27€7k
Plant, machinery and equipment23€7k
Current assets29/58€416k
Stocks and contracts in progress3€164k
Stocks30/36€164k
Amounts receivable within one year40/41€151k
Trade receivables40€117k
Other amounts receivable41€35k
Cash at bank and in hand54/58€101k
Equity and liabilities
Total equity and liabilities10/49€1.06M
Equity10/15€14k
Reserves13€14k
Distributable reserves133€14k
Amounts payable17/49€1.05M
Amounts payable within one year42/48€1.05M
Trade debts44€50k
Suppliers440/4€50k
Taxes, remuneration and social security45€53k
Taxes450/3€53k
Other amounts payable47/48€944k
Income statement
Code2025
Remuneration, social security and pensions62€326k
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€65k
Other operating charges640/8€423
Gross operating margin9900€414k
Operating profit (loss)9901€22k
Financial income75/76B€15
Recurring financial income75€15
Financial charges65/66B€3k
Recurring financial charges65€3k
Profit (loss) for the period before taxes9903€20k
Income taxes67/77€5k
Profit (loss) for the period9904€14k
Profit (loss) for the period to be appropriated9905€14k
Appropriation of the result
Profit (loss) to be appropriated9906€14k
Transfer to equity691/2€14k
To other reserves6921€14k
Social balance
Average headcount (FTE)90874.7
The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2026
27-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 27 days late
NBB filing
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Montigny-le-Tilleul · 1 establishment unit since 2024
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue du Faubourg 1296110 Montigny-le-TilleulGround area
4,476 m²
Building footprint
346 m²
Volume, LiDAR
2,800 m³
2 parcels, Wallonia · tallest building 11.9 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
PHARMA WILSON
since 20242.367.965.384
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52048C0139/00A000 | Wallonia | 4,246 m² | 1 · 221 m² | 8.5 m · 2 fl. |
| 52502B0530/03R000 | Wallonia | 231 m² | 1 · 126 m² | 11.9 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
T.R.F. pharma
BE 1017.867.223
Fléron · Eq €14k
Apotheker Van De Weghe Karen
BE 0662.425.965
Deinze · Eq €14k
JETPHARMA
BE 0508.755.793
Jette · Eq €14k
Sagenex
BE 0460.691.897
Namur · Eq €14k
ES PHARMA
BE 1009.079.320
Mol · Eq €14k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 1,105 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded26-11-2024
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 1 filingAddress and cadastre registers
Data from official sources, last processed on 12-09-2026. Scores and ratios are computed by Checked and are not a credit decision.